ASCLS eNewsBytes

• Over 5M Americans could benefit if psilocybin approved for depression September 16, 2024
  Researchers estimate that if the FDA approves the psychedelic psilocybin for depression treatment, over 5 million Americans could benefit. The drug, previously considered an illicit drug, has undergone a rebirth in recent years, with studies suggesting it might help ease depression when given in a controlled, supervised manner.
• What to know about Letybo, the newest injectable neurotoxin to get FDA approval September 16, 2024
  Botox, once the only injectable neurotoxin, now faces competition from Dysport, Jeuveau, Xeomin and Daxxify. Letybo, a new neurotoxin, has received FDA approval and is expected to be available later this year. It is a "me too" product, similar to other neurotoxins but with a longer history of safety.
• Report: National wastewater surveillance should be continued to prevent future pandemics September 16, 2024
  A report by Washington State University's Guy Palmer suggests the National Wastewater Surveillance System should transition to a broader system for detecting prevalent and emerging pathogens. The report argues that addressing shortcomings in the current system can elevate the public value of wastewater data and provide nimble public health responses.
• VP of Withings Health Solutions talks newly FDA approved Sleep RX device September 16, 2024
  Withings has received FDA clearance for its Sleep Rx device, which can screen adults with suspected sleep breathing disorders to diagnose Obstructive Sleep Apnea, sleep analysis and heart rate estimation. The device fits under any mattress, eliminating the need for masks or cumbersome equipment.
• FDA approves first subcutaneous PD-L1 inhibitor for multiple cancers September 16, 2024
  The FDA has approved atezolizumab and hyaluronidase-tqjs for subcutaneous injection, covering adult indications of the intravenous formulation of atezolizumab. This marks the first subcutaneous PD-L1 inhibitor to receive FDA approval, and it can be administered within seven minutes compared to intravenous infusions.